Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study

Abstract Background Afatinib is one of the standard treatments for patients with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). However, data on the use of afatinib in patients with poor performance status (PS ≥ 2) are limited. This study aimed to retrospectively...

Description complète

Détails bibliographiques

Auteurs principaux:	Chiao-En Wu, Ching-Fu Chang, Chen-Yang Huang, Cheng-Ta Yang, Chih-Hsi Scott Kuo, Ping-Chih Hsu, John Wen-Cheng Chang
Format:	Artigo
Langue:	Inglês
Publié:	BMC 2021-07-01
Collection:	BMC Cancer
Sujets:	Lung cancer Afatinib EGFR TKI Performance status
Accès en ligne:	https://doi.org/10.1186/s12885-021-08587-w
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!